231 related articles for article (PubMed ID: 31818505)
1. [Treatment of noninfectious intermediate uveitis, posterior uveitis, or panuveitis].
Couret C; Ducloyer JB; Touhami S; Angioi-Duprez K; Rougier MB; Labalette P; Titah C; Cochereau I; Kodjikian L; Mura F; Chiquet C; Weber M; Bodaghi B
J Fr Ophtalmol; 2020 Apr; 43(4):341-361. PubMed ID: 31818505
[TBL] [Abstract][Full Text] [Related]
2. Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.
; Kempen JH; Altaweel MM; Drye LT; Holbrook JT; Jabs DA; Sugar EA; Thorne JE
Ophthalmology; 2015 Oct; 122(10):1967-75. PubMed ID: 26298715
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis: Evolution through Preclinical and Clinical Studies.
Nguyen QD; Merrill PT; Sepah YJ; Ibrahim MA; Banker A; Leonardi A; Chernock M; Mudumba S; Do DV
Ophthalmology; 2018 Dec; 125(12):1984-1993. PubMed ID: 30060978
[TBL] [Abstract][Full Text] [Related]
4. Multimodal imaging in infectious and noninfectious intermediate, posterior and panuveitis.
Thomas AS; Lin P
Curr Opin Ophthalmol; 2021 May; 32(3):169-182. PubMed ID: 33710009
[TBL] [Abstract][Full Text] [Related]
5. Successful multi-modality approach in management of human leukocyte antigen-B27 associated fulminant panuveitis - rare presentation.
Kumar A; Ambiya V; Kapoor G; Arora A
Rom J Ophthalmol; 2018; 62(4):304-307. PubMed ID: 30891528
[No Abstract] [Full Text] [Related]
6. [Not Available].
Ophthalmologe; 2014 Sep; 111(9):814. PubMed ID: 25343167
[No Abstract] [Full Text] [Related]
7. Current approach in the diagnosis and management of panuveitis.
Bansal R; Gupta V; Gupta A
Indian J Ophthalmol; 2010; 58(1):45-54. PubMed ID: 20029145
[TBL] [Abstract][Full Text] [Related]
8. Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results.
Jaffe GJ; Lin P; Keenan RT; Ashton P; Skalak C; Stinnett SS
Ophthalmology; 2016 Sep; 123(9):1940-8. PubMed ID: 27421623
[TBL] [Abstract][Full Text] [Related]
9. Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
Dick AD; Tundia N; Sorg R; Zhao C; Chao J; Joshi A; Skup M
Ophthalmology; 2016 Mar; 123(3):655-62. PubMed ID: 26712559
[TBL] [Abstract][Full Text] [Related]
10. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.
Nussenblatt RB; Peterson JS; Foster CS; Rao NA; See RF; Letko E; Buggage RR
Ophthalmology; 2005 May; 112(5):764-70. PubMed ID: 15878055
[TBL] [Abstract][Full Text] [Related]
11. Optical coherence tomography in uveitis patients.
Hassenstein A; Bialasiewicz AA; Richard G
Am J Ophthalmol; 2000 Nov; 130(5):669-70. PubMed ID: 11078850
[TBL] [Abstract][Full Text] [Related]
12. Oral corticosteroid exposure and increased risk of related complications in patients with noninfectious intermediate, posterior, or panuveitis: Real-world data analysis.
Chirikov VV; Shah R; Kwon Y; Patel D
Ophthalmic Epidemiol; 2019 Feb; 26(1):27-46. PubMed ID: 30199301
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
Suhler EB; Jaffe GJ; Fortin E; Lim LL; Merrill PT; Dick AD; Brezin AP; Nguyen QD; Thorne JE; Van Calster J; Cimino L; Adan A; Goto H; Kaburaki T; Kramer M; Vitale AT; Kron M; Song AP; Liu J; Pathai S; Douglas KM; Schlaen A; Muccioli C; Van Velthoven MEJ; Zierhut M; Rosenbaum JT
Ophthalmology; 2021 Jun; 128(6):899-909. PubMed ID: 33157077
[TBL] [Abstract][Full Text] [Related]
14. [Intermediate and Posterior Uveitis - Disease entities].
Baquet-Walscheid K; Heinz C
Klin Monbl Augenheilkd; 2024 Jan; 241(1):119-135. PubMed ID: 37977201
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
Al-Janabi A; El Nokrashy A; Sharief L; Nagendran V; Lightman S; Tomkins-Netzer O
Ophthalmology; 2020 Mar; 127(3):410-416. PubMed ID: 31607412
[TBL] [Abstract][Full Text] [Related]
16. Ocular Autoimmune Systemic Inflammatory Infectious Study - Report 3: Posterior and Panuveitis.
Lee JH; Mi H; Lim R; Ho SL; Lim WK; Teoh SC; Agrawal R
Ocul Immunol Inflamm; 2019; 27(1):89-98. PubMed ID: 28991501
[TBL] [Abstract][Full Text] [Related]
17. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.
Sheppard J; Joshi A; Betts KA; Hudgens S; Tari S; Chen N; Skup M; Dick AD
JAMA Ophthalmol; 2017 Jun; 135(6):511-518. PubMed ID: 28426849
[TBL] [Abstract][Full Text] [Related]
18. [Diagnostic Strategy and Therapeutic Dilemma in Acute Posterior and Panuveitis].
Garweg JG; Messerli J
Klin Monbl Augenheilkd; 2019 Apr; 236(4):487-491. PubMed ID: 30763960
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressants used in a steroid-sparing strategy for childhood uveitis.
Schatz CS; Uzel JL; Leininger L; Danner S; Terzic J; Fischbach M
J Pediatr Ophthalmol Strabismus; 2007; 44(1):28-34. PubMed ID: 17274332
[TBL] [Abstract][Full Text] [Related]
20. [Epidemiology of uveitis].
Guex-Crosier Y
Rev Prat; 1999 Nov; 49(18):1989-94. PubMed ID: 10626483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
